|
|
||||||||
Oregon National Primate Research Center and Department of Physiology and Pharmacology Oregon Health & Science University 505 NW 185th Avenue Beaverton, OR 97006
Correspondence: Address correspondence to PMC. E-mail connm{at}ohsu.edu; fax 503-690-5569.

Receptor mutations that elicit loss of function are sometimes equated with defects that ablate receptor-ligand binding or receptor-effector interactions. Similarly, mutationally defective enzymes and ion channels are often viewed as compromised in substrate or ion recognition, respectively. Recent observations, however, suggest that an alternate mechanism may be surprisingly common, namely, that mutations in structural genes may not interfere with the inherent functionality of the affected protein, but nevertheless cause disease by preventing the cells trafficking machinery from placing the affected protein at the appropriate subcellular compartment (e.g., at the cell membrane). Accordingly, therapies may be devised to ensure the placement of receptors (or other proteins) at locations where they can support cell function.
This article has been cited by other articles:
![]() |
T. T. Chung, T. R. Webb, L. F. Chan, S. N. Cooray, L. A. Metherell, P. J. King, J. P. Chapple, and A. J. L. Clark The Majority of Adrenocorticotropin Receptor (Melanocortin 2 Receptor) Mutations Found in Familial Glucocorticoid Deficiency Type 1 Lead to Defective Trafficking of the Receptor to the Cell Surface J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4948 - 4954. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Janovick, S. P. Brothers, P. E. Knollman, and P. M. Conn Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand FASEB J, February 1, 2007; 21(2): 384 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P Brothers, J. A. Janovick, and P M. Conn Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression J. Mol. Endocrinol., December 1, 2006; 37(3): 479 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Conn, P. E. Knollman, S. P. Brothers, and J. A. Janovick Protein Folding as Posttranslational Regulation: Evolution of a Mechanism for Controlled Plasma Membrane Expression of a G Protein-Coupled Receptor Mol. Endocrinol., December 1, 2006; 20(12): 3035 - 3041. [Abstract] [Full Text] [PDF] |
||||
![]() |
P M. Conn, J. A. Janovick, S. P Brothers, and P. E Knollman 'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation. J. Endocrinol., July 1, 2006; 190(1): 13 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Janovick, P. E. Knollman, S. P. Brothers, R. Ayala-Yanez, A. S. Aziz, and P. M. Conn Regulation of G Protein-coupled Receptor Trafficking by Inefficient Plasma Membrane Expression: MOLECULAR BASIS OF AN EVOLVED STRATEGY J. Biol. Chem., March 31, 2006; 281(13): 8417 - 8425. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Castro-Fernandez, G. Maya-Nunez, and P. M. Conn Beyond the Signal Sequence: Protein Routing in Health and Disease Endocr. Rev., June 1, 2005; 26(4): 479 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Leanos-Miranda, A. Ulloa-Aguirre, J. A. Janovick, and P. M. Conn In Vitro Coexpression and Pharmacological Rescue of Mutant Gonadotropin-Releasing Hormone Receptors Causing Hypogonadotropic Hypogonadism in Humans Expressing Compound Heterozygous Alleles J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3001 - 3008. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Pask, H. Kanasaki, U. B. Kaiser, P. M. Conn, J. A. Janovick, D. W. Stockton, D. L. Hess, M. J. Justice, and R. R. Behringer A Novel Mouse Model of Hypogonadotrophic Hypogonadism: N-Ethyl-N-Nitrosourea-Induced Gonadotropin-Releasing Hormone Receptor Gene Mutation Mol. Endocrinol., April 1, 2005; 19(4): 972 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Brothers, A. Cornea, J. A. Janovick, and P. M. Conn Human Loss-of-Function Gonadotropin-Releasing Hormone Receptor Mutants Retain Wild-Type Receptors in the Endoplasmic Reticulum: Molecular Basis of the Dominant-Negative Effect Mol. Endocrinol., July 1, 2004; 18(7): 1787 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley Gonadotropin-Releasing Hormone Receptors Endocr. Rev., April 1, 2004; 25(2): 235 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Brothers, J. A. Janovick, and P. M. Conn Unexpected Effects of Epitope and Chimeric Tags on Gonadotropin-Releasing Hormone Receptors: Implications for Understanding the Molecular Etiology of Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6107 - 6112. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Leanos-Miranda, A. Ulloa-Aguirre, T. H. Ji, J. A. Janovick, and P. M. Conn Dominant-Negative Action of Disease-Causing Gonadotropin-Releasing Hormone Receptor (GnRHR) Mutants: A Trait That Potentially Coevolved with Decreased Plasma Membrane Expression of GnRHR in Humans J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3360 - 3367. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Janovick, M. Goulet, E. Bush, J. Greer, D. G. Wettlaufer, and P. M. Conn Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 608 - 614. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |